Clinical trials: Immunoglobulin G4 Related Disease
Lupus Nephritis, IgG4-related Disease
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
A Clinical Study on the Safety and Effectiveness of BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Lupus Nephritis and IgG4-Related Disease.
- Trial name
- NCT06497387
- Testing
- PRG-1801
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
Immunoglobulin G4-Related Disease
Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
Immunoglobulin G4-related disease (IgG4-RD) is a chronic immune-mediated disorder characterized by inflammation, fibrosis, and involvement of multiple organs.
- Trial name
- LENITY (NCT07719543)
- Testing
- Lenalidomide
- Where
- 3 sites in China
- Volunteers
- 146 people
- Sponsor
- Chinese PLA General Hospital
IgG4-Related Diseases
Key Mechanisms of Abnormal T Cell Activation and Differentiation in IgG4-Related Ophthalmic Disease
IgG4-related disease (IgG4-RD) is a newly recognized chronic inflammatory condition caused by immune system dysfunction. It is characterized by the infiltration of IgG4+ plasma cells, dense fibrosis, and inflammation involving…
- Trial name
- NCT06655831
- Volunteers
- 20 people
- Sponsor
- Peking University Third Hospital
Immunoglobulin G4-Related Disease
Study of the C5a/C5aR1 Axis in IgG4-associated Disease: a Potential Therapeutic Target
This is a monocentric, comparative, cross-sectional, case-control study seeking to identify abnormalities of the C5a-C5aR1 axis between a population of patients with active IgG4-associated disease (MAG4) and two control groups…
- Trial name
- C5-MAG4 (NCT06270524)
- Testing
- Blood sampling
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Rare Diseases, Amyloidosis
Institutional Registry of Rare Diseases
The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).
- Conditions
- Rare Diseases, Amyloidosis, Sarcoidosis, Phacomatosis
- Trial name
- NCT06573723
- Where
- Argentina
- Volunteers
- 380 people
- Sponsor
- Hospital Italiano de Buenos Aires
Autoimmune Pancreatitis, IgG4-Related Diseases
Validation of the Odesa Criteria 2026 for Autoimmune Pancreatitis
This ambispective observational study aims to validate the Odesa Criteria 2026 (OC26), a flexible domain-based point scoring system for diagnosing autoimmune pancreatitis.
- Conditions
- Autoimmune Pancreatitis, IgG4-Related Diseases, Pancreatic Cancer, Chronic Pancreatitis
- Trial name
- ОС26 (NCT07536841)
- Testing
- No intervention (observational study)
- Where
- 2 sites in Ukraine
- Volunteers
- 82 people
- Sponsor
- Military Medical Clinical Center of the Southern Region, Ukraine
IgG4 Related Disease, B-cell Mediated Autoimmune Disorders
Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
The goal of this clinical trial is to test the safety and potential benefit of a new immune cell therapy called anti-BCMA-CD19 CAR-T cells in adults (18-75 years) with IgG4-related disease (IgG4-RD) that has come back or not…
- Trial name
- BC19IGG4 (NCT07148791)
- Testing
- Anti-BCMA-CD19 CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Chinese PLA General Hospital
IgG4-related Disease With Eosinophilia
Baricitinib Plus Glucocorticoid for Eosinophilia in IgG4-RD
Evaluation of efficacy and safety of Baricitinib combined with glucocorticoid in patients of IgG4-related disease with eosinophilia.
- Trial name
- NCT05781516
- Testing
- Prednisolone, Baricitinib
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Wen Zhang
Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc)
A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases
This study evaluates the safety and efficacy of YTS109 cells in adults with relapsed/refractory autoimmune diseases, such as Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), etc.
- Conditions
- Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Trial name
- NCT06978647
- Testing
- YTS109 cell
- Where
- China
- Volunteers
- 12 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
IgG4 Related Disease, Covid19
Impact of COVID-19 on the Clinical Outcomes and Management of IgG4 Related Disease Patients
Since December 2019, coronavirus disease 2019 (COVID-19), caused by the severe respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected more than 124 million people worldwide as of 23/3/2021.
- Trial name
- IgG4-COVID (NCT04817553)
- Testing
- exposure to COVID19
- Where
- Hong Kong
- Volunteers
- 124 people
- Sponsor
- Chinese University of Hong Kong
Immunoglobulin G4 Related Disease
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
This is a Phase 3, parallel group, 2-arm, randomized, double blind, placebo-controlled, 52-week treatment study to assess the efficacy and safety of rilzabrutinib as a treatment for adult patients with active IgG4-RD.
- Trial name
- RILIEF (NCT07190196)
- Testing
- Rilzabrutinib, Glucocorticoid
- Where
- 95 sites in United States, Argentina and 17 more
- Volunteers
- 124 people
- Sponsor
- Sanofi
IgG4 Related Disease, IgG4-RD
Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)
This is a two-part multi-center clinical trial in participants with active IgG4-RD. Part 1 (Cohort 1a and Cohort 1B) is an open-label, dose escalation phase to determine the safety of elotuzumab for investigation in IgG4-RD.
- Trial name
- NCT04918147
- Testing
- elotuzumab, methylprednisolone, diphenhydramine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
IgG4-related Disease
Tofatib Treatment for IgG4-related Disease
Compared with cyclophosphamide, the efficacy and safety of tofacitinib in the treatment of active IgG4-related diseases were evaluated.
- Trial name
- NCT05625581
- Testing
- tofacitinib
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Changhai Hospital
Undiagnosed IgG4 Related Diseases
Retrospective Study for Diagnosis of Undetected IgG4 Related Diseases in Patients With High Serum IgG4 Levels.
Immunoglobulin G4-related disease (IgG4-RD) is an increasingly recognized syndrome of unknown etiology comprised of a collection of disorders that share specific pathologic, serologic, and clinical features.
- Trial name
- NCT02229448
- Where
- Israel
- Volunteers
- 11 people
- Sponsor
- Meir Medical Center
Immunoglobulin G4-related Disease
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD), as well as to assess the safety and tolerability, of inebilizumab in pediatric participants with IgG4-RD.
- Trial name
- NCT07222553
- Testing
- Inebilizumab
- Where
- 14 sites in United States, Brazil and 5 more
- Volunteers
- 15 people
- Sponsor
- Amgen
IgG4-related Disease
Glucocorticoids in Patients With IgG4-RD
This is a randomized, open-label, single-center clinical trial to compare the efficacy and safety profile for medium-dose versus high dose glucocorticoid in patients with IgG4-related Disease.
- Trial name
- NCT01758393
- Testing
- Prednisone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking Union Medical College Hospital
Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies
Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases
Main purpose: To evaluate the safety of UTAA09 injection in the treatment of relapsed/refractory (R/R) autoimmune disease (AID).
- Conditions
- Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, IgG4 Related Disease
- Trial name
- NCT06361745
- Testing
- T cell injection targeting CD19 chimeric antigen receptor
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Immunoglobulin G4 Related Sclerosing Disease
Leflunomide for Maintenance of Remission in IgG4 Related Disease
The study has been designed as a 12-month, open-label, randomized, controlled study comparing the use of prednisone mono-therapy and prednisone and leflunomide combination therapy in treating patients with IgG4-related disease.
- Trial name
- NCT02703194
- Testing
- Prednisone, Leflunomide
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Chinese PLA General Hospital
IgG4-related Disease
Short-term Glucocorticoid Combined with MMF for IgG4-RD
Comparison of short-term glucocorticoid monotherapy and short-term glucocorticoid combined with MMF in the treatment of IgG4 Related Disease
- Trial name
- NCT06663618
- Testing
- prednison, Mycophenolate mofetil
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Wen Zhang
IgG4-related Disease
BCT301 in Treating Refractory/Recurrent IgG4-related Disease
This is an investigator initiated trial to assess the safety and efficacy of BCT301 cell Injection (CAR-iT cells derived from chemically induced pluripotent stem cells) in patients with refractory/recurrent IgG4-related disease.
- Trial name
- NCT07793903
- Testing
- BCT301 Cell Injection
- Volunteers
- 6 people
- Sponsor
- Peking University Third Hospital